Cadrenal Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.985 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.51M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatm...